E4CPG (3-30 nmol/site (i.t.), 1-10 μmol/paw (i.pl.), and 1-10 nmol/site (i.c.v.)) significantly inhibits the nociception induced by the Glutamate-injection (i.pl.; 30 μmol/paw), and the maximal inhibition values for the antinociceptive action of E4CPG in Glutamate-induced nociception are 48% (i.pl.), 49% (i.t.) and 40% (i.c.v.) .
E4CPG (35 nM/3.5 μL, i.c.v.) completely blocks long-term depression (LTD) induced by the group I mGluR agonist Dihydroxyphenylglycine (DHPG, 100 nM/5 μL, i.c.v.) in male Sprague-Dawley rats.
| Animal Model: |
Male Swiss mice (25-35 g) |
| Dosage: |
3-30 nmol/site (i.t.), 1-10 μmol/paw (i.pl.) and 1-10 nmol/ site (i.c.v.)
|
| Administration: |
Single injection |
| Result: |
The maximal inhibition values for the antinociceptive action of E4CPG in glutamate-induced
nociception were 48% (i.pl.), 49% (i.t.) and 40% (i.c.v.).
|
| Animal Model: |
Male Sprague-Dawley rats |
| Dosage: |
35 nM/3.5 μL |
| Administration: |
Single injection, i.c.v. |
| Result: |
Completely blocked LTD induced by the group I mGluR agonist dihydroxyphenylglycine (DHPG). |